Security key
61559X104
MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX)
CUSIP: 61559X104
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Class A ordinary share, par value $0.0001 per share
- Total 13F shares
- 60,656,094
- Total 13F value
- $2,667,012,692
- Share change
- +1,314,862
- Put/Call ratio
- 75%
- SEC-reported price per share
- $43.97
- Number of holders
- 109
- Value change
- +$45,095,266
- Number of buys
- 56
- Number of sells
- 61
- Shares outstanding
- 81,224,792
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
109
Top holders
10
MLTX full security history
Ownership snapshot
Full 13F holder table
MoonLake Immunotherapeutics SEC filings
MoonLake Immunotherapeutics company facts
Broader feeds
Ownership snapshot
Top reported holders of MLTX - MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BVF INC/IL
Disclosed value leader
BVF INC/IL
Comparable rows
15/15
Latest evidence
31 Mar 2024
13F
Lead comparable stake: 27%
Showing 1-6 of 15 holder rows.
Quick read
BVF INC/IL leads the comparable SEC ownership view at 27%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BVF INC/IL's linked filing trail.
Comparable ownership
Top 5
BVF INC/IL
27%
Cormorant Asset Management, LP
10%
FMR LLC
5.4%
Avoro Capital Advisors LLC
3.2%
CITADEL ADVISORS LLC
2.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BVF INC/IL |
13F
Company
|
27%
|
$1,092,566,995
21,751,284 shares
|
— | 31 Mar 2024 |
| Cormorant Asset Management, LP |
13F
Company
|
10%
|
$426,661,205
8,494,151 shares
|
— | 31 Mar 2024 |
| FMR LLC |
13F
Company
|
5.4%
|
$219,537,849
4,370,652 shares
|
— | 31 Mar 2024 |
| Avoro Capital Advisors LLC |
13F
Company
|
3.2%
|
$129,593,400
2,580,000 shares
|
— | 31 Mar 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
2.8%
|
$116,002,820
2,309,433 shares
|
— | 31 Mar 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
2.8%
|
$114,771,180
2,284,913 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
109
Shares
60,656,094
Rows available
109
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
112
Q2 2024 holders
109
Holder diff
-3
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|